Evaluation of the potential interaction between daclatasvir and MK 5172 in healthy volunteers.

Trial Profile

Evaluation of the potential interaction between daclatasvir and MK 5172 in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2013

At a glance

  • Drugs Daclatasvir (Primary) ; Grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 21 Oct 2013 New trial record
    • 01 Oct 2013 Results will be presented at the 64th Annual Meeting of The American Association for the Study of Liver Diseases (AASLD) according to a Bristol-Myers Squibb media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top